In the article cited above, Recommendation 11.3c stated “In patients with chronic kidney disease who are at increased risk for cardiovascular events or chronic kidney disease progression and are unable to use a sodium–glucose cotransporter 2 inhibitor, a nonsteroidal mineralocorticoid receptor antagonist (finerenone) is recommended to reduce chronic kidney disease progression and cardiovascular events.” The correct text is “In patients with chronic kidney disease who are at increased risk for cardiovascular events or chronic kidney disease progression or are unable to use a sodium–glucose cotransporter 2 inhibitor, a nonsteroidal mineralocorticoid receptor antagonist (finerenone) is recommended to reduce chronic kidney disease progression and cardiovascular events.”
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar